Article Information
PubMed
Published By
History
- Received October 11, 2017
- Returned for modification November 5, 2017
- Accepted December 18, 2017
- Published online February 23, 2018.
Copyright & Usage
Copyright © 2018 American Society for Microbiology. All Rights Reserved.
Article Versions
- Accepted Manuscript version (January 08, 2018).
- You are viewing the most recent version of this article.
Author Information
- Christopher M. Rubinoa,
- Sujata M. Bhavnania,
- Jeffery S. Loutitb,
- Brooke Lohseb,
- Michael N. Dudleyb and
- David C. Griffithb
- aInstitute for Clinical Pharmacodynamics, Schenectady, New York, USA
- bThe Medicines Company, San Diego, California, USA
- Address correspondence to David C. Griffith, david.griffith{at}themedco.com.
Citation Rubino CM, Bhavnani SM, Loutit JS, Lohse B, Dudley MN, Griffith DC. 2018. Single-dose pharmacokinetics and safety of meropenem-vaborbactam in subjects with chronic renal impairment. Antimicrob Agents Chemother 62:e02103-17. https://doi.org/10.1128/AAC.02103-17.